Oleg N. Vassiliev

Validation of a new grid-based Boltzmann equation solver for dose calculation in radiotherapy with photon beams

A new grid-based Boltzmann equation solver, Acuros, was developed specifically for performing accurate and rapid radiotherapy dose calculations. In this study we benchmarked its performance against Monte Carlo for 6 and 18 MV photon beams in heterogeneous media. Acuros solves the coupled Boltzmann transport equations for neutral and charged particles on a locally adaptive Cartesian grid. The Acuros solver is an optimized rewrite of the general purpose Attila software, and for comparable accuracy levels, it is roughly an order of magnitude faster than Attila. Comparisons were made between Monte Carlo (EGSnrc) and Acuros for 6 and 18 MV photon beams impinging on a slab phantom comprising tissue, bone and lung materials. To provide an accurate reference solution, Monte Carlo simulations were run to a tight statistical uncertainty (sigma approximately 0.1%) and fine resolution (1-2 mm). Acuros results were output on a 2 mm cubic voxel grid encompassing the entire phantom. Comparisons were also made for a breast treatment plan on an anthropomorphic phantom. For the slab phantom in regions where the dose exceeded 10% of the maximum dose, agreement between Acuros and Monte Carlo was within 2% of the local dose or 1 mm distance to agreement. For the breast case, agreement was within 2% of local dose or 2 mm distance to agreement in 99.9% of voxels where the dose exceeded 10% of the prescription dose. Elsewhere, in low dose regions, agreement for all cases was within 1% of the maximum dose. Since all Acuros calculations required less than 5 min on a dual-core two-processor workstation, it is efficient enough for routine clinical use. Additionally, since Acuros calculation times are only weakly dependent on the number of beams, Acuros may ideally be suited to arc therapies, where current clinical algorithms may incur long calculation times.

Dosimetric properties of photon beams from a flattening filter free clinical accelerator

Basic dosimetric properties of 6 MV and 18 MV photon beams from a Varian Clinac 21EX accelerator operating without the flattening filter have been measured. These include dose rate data, depth dose dependencies and lateral profiles in a water phantom, total scatter factors and transmission factors of a multileaf collimator. The data are reviewed and compared with measurements for the flattened beams. The unflattened beams have the following: a higher dose rate by factors of 2.3 (6 MV) and 5.5 (18 MV) on the central axis; lower out-of-field dose due to reduced head scatter and softer spectra; less variation of the total scatter factor with field size; and less variation of the shape of lateral dose profiles with depth. The findings suggest that with a flattening filter free accelerator better radiation treatments can be developed, with shorter delivery times and lower doses to normal tissues and organs.

A flattening filter free photon treatment concept evaluation with Monte Carlo

In principle, the concept of flat initial radiation-dose distribution across the beam is unnecessary for intensity modulated radiation therapy. Dynamic leaf positioning during irradiation could appropriately adjust the fluence distribution of an unflattened beam that is peaked in the center and deliver the desired uniform or nonuniform dose distribution. Removing the flattening filter could lead to reduced treatment time through higher dose rates and reduced scatter, because there would be substantially less material in the beam; and possibly other dosimetric and clinical advantages. This work aims to evaluate the properties of a flattening filter free clinical accelerator and to investigate its possible advantages in clinical intensity modulated radiation therapy applications by simulating a Varian 2100-based treatment delivery system with Monte Carlo techniques. Several depth-dose curves and lateral dose distribution profiles have been created for various field sizes, with and without the flattening filter. Data computed with this model were used to evaluate the overall quality of such a system in terms of changes in dose rate, photon and electron fluence, and reduction in out-of-field stray dose from the scattered components and were compared to the corresponding data for a standard treatment head with a flattening filter. The results of the simulations of the flattening filter free system show that a substantial increase in dose rate can be achieved, which would reduce the beam on time and decrease the out-of-field dose for patients due to reduced head-leakage dose. Also close to the treatment field edge, a significant improvement in out-of-field dose could be observed for small fields, which can be attributed to the change in the photon spectra, when the flattening filter is removed from the beamline.

Properties of unflattened photon beams shaped by a multileaf collimator.

Several studies have shown that removal of the flattening filter from the treatment head of a clinical accelerator increases the dose rate and changes the lateral profile in radiation therapy with photons. However, the multileaf collimator (MLC) used to shape the field was not taken into consideration in these studies. We therefore investigated the effect of the MLC on flattened and unflattened beams. To do this, we performed measurements on a Varian Clinac 21EX and MCNPX Monte Carlo simulations to analyze the physical properties of the photon beam. We compared lateral profiles, depth dose curves, MLC leakages, and total scatter factors for two energies (6 and 18 MV) of MLC-shaped fields and jaw-shaped fields. Our study showed that flattening filter-free beams shaped by a MLC differ from the jaw-shaped beams. Similar differences were also observed for flattened beams. Although both collimating methods produced identical depth dose curves, the penumbra size and the MLC leakage were reduced in the softer, unflattened beam and the total scatter factors showed a smaller field size dependence.

Monte Carlo study of photon fields from a flattening filter-free clinical accelerator

In conventional clinical linear accelerators, the flattening filter scatters and absorbs a large fraction of primary photons. Increasing the beam-on time, which also increases the out-of-field exposure to patients, compensates for the reduction in photon fluence. In recent years, intensity modulated radiation therapy has been introduced, yielding better dose distributions than conventional three-dimensional conformal therapy. The drawback of this method is the further increase in beam-on time. An accelerator with the flattening filter removed, which would increase photon fluence greatly, could deliver considerably higher dose rates. The objective of the present study is to investigate the dosimetric properties of 6 and 18 MV photon beams from an accelerator without a flattening filter. The dosimetric data were generated using the Monte Carlo programs BEAMnrc and DOSXYZnrc. The accelerator model was based on the Varian Clinac 2100 design. We compared depth doses, dose rates, lateral profiles, doses outside collimation, total and collimator scatter factors for an accelerator with and without a flatteneing filter. The study showed that removing the filter increased the dose rate on the central axis by a factor of 2.31 (6 MV) and 5.45 (18 MV) at a given target current. Because the flattening filter is a major source of head scatter photons, its removal from the beam line could reduce the out-of-field dose.

A Monte Carlo model for calculating out-of-field dose from a Varian 6 MV beam

Dose to the patient outside of the treatment field is important when evaluating the outcome of radiotherapy treatments. However, determining out-of-field doses for any particular treatment plan currently requires either time-consuming measurements or calculated estimations that may be highly uncertain. A Monte Carlo model may allow these doses to be determined quickly, accurately, and with a great degree of flexibility. MCNPX was used to create a Monte Carlo model of a Varian Clinac 2100 accelerator head operated at 6MV. Simulations of the dose out-of-field were made and measurements were taken with thermoluminescent dosimeters in an acrylic phantom and with an ion chamber in a water tank to validate the Monte Carlo model. Although local differences between the out-of-field doses calculated by the model and those measured did exceed 50% at some points far from the treatment field, the average local difference was only 16%. This included a range of doses as low as 0.01% of the central axis dose, and at distances in excess of 50cm from the central axis of the treatment field. The out-of-field dose was found to vary with field size and distance from the central axis, but was almost independent of the depth in the phantom except where the dose increased substantially at depths less than dmax. The relationship between dose and kerma was also investigated, and kerma was found to be a good estimate of dose (within 3% on average) except near the surface and in the field penumbra. Our Monte Carlo model was found to well represent typical Varian 2100 accelerators operated at 6MV.

Out-of-field photon dose following removal of the flattening filter from a medical accelerator

The aim of this paper is to determine the effect of removing the flattening filter from a linear accelerator on the out-of-field photon dose. A Monte Carlo model was used to simulate 6 MV and 18 MV photon beams from a Varian 2100 accelerator with the flattening filter in place and with it removed. The out-of-field photon doses and composition (head leakage, patient scatter and collimator scatter) were calculated from square open fields in a water tank as a function of distance from central axis, field size and depth. The out-of-field doses resulting from intensity-modulated radiation therapy to the prostate at 6 MV were also calculated, with and without the flattening filter, to sensitive organs in an anthropomorphic Rando phantom. Removal of the flattening filter reduced the out-of-field dose near the treatment field (<3 cm from the field edge) because of decreased collimator scatter. It increased the out-of-field dose at intermediate distances from the field edge (3-15 cm) because of increased patient scatter. At greater distances, the out-of-field dose was decreased because of reduced head leakage. For the clinical treatment examined, the out-of-field dose was generally reduced following removal of the flattening filter, particularly at large distances from the treatment field. Removal of the flattening filter may be advantageous by reducing the out-of-field dose to the patient. This could contribute to reducing the long-term risk of secondary malignancies. In general, however, the out-of-field dose depends on treatment and patient parameters, and a reduction may not always be achievable.

Stereotactic radiotherapy for lung cancer using a flattening filter free Clinac

The objective of this study was to assess the feasibility of stereotactic radiotherapy for early stage lung cancer using photon beams from a Varian Clinac accelerator operated without a flattening filter. Treatment plans were generated for 10 lung cancer patients with isolated lesions less than 3 cm in diameter. For each patient, two plans were generated, one with and one without the flattening filter. Plans were generated with Eclipse 8.0 (Varian Medical Systems) commissioned with beam data measured on a Clinac 21EX (Varian Medical Systems) operated with and without the flattening filter. Removal of the flattening filter increased the dose rate. The median beam‐on time per field was reduced from 25 sec (with the filter) to 11 sec (without the filter), increasing the feasibility of breath‐hold treatments and the efficiency of gated treatments. Differences in a dose heterogeneity index for the planning target volume between plans with flattened and unflattened beams were statistically insignificant. Differences in mean doses to organs at risk were small, typically about 10 cGy over the entire treatment. The study concludes that radiotherapy with unflattened beams is feasible and requires substantially less beam‐on time, facilitating breath‐hold and gating techniques. PACS numbers: 87.56.bd, 87.53.Ly

Monte Carlo investigation of collimator scatter of proton-therapy beams produced using the passive scattering method

As a proton-therapy beam passes through the field-limiting aperture, some of the protons are scattered off the edges of the collimator. The edge-scattered protons can degrade the dose distribution in a patient or phantom, and these effects are difficult to model with analytical methods such as those available in treatment planning systems. The objective of this work was to quantify the dosimetric impact of edge-scattered protons for a representative variety of clinical treatment beams. The dosimetric impact was assessed using Monte Carlo simulations of proton beams from a contemporary treatment facility. The properties of the proton beams were varied, including the penetration range (6.4-28.5 cm), width of the spread-out Bragg peak (SOBP; 2-16 cm), field size (3 x 3 cm(2) to 15 x 15 cm(2)) and air gap, i.e. the distance between the collimator and the phantom (8-48 cm). The simulations revealed that the dosimetric impact of edge-scattered protons increased strongly with increasing range (dose increased by 6-20% with respect to the dose at the center of the spread-out Bragg peak), decreased strongly with increasing field size (dose changed by 2-20%), increased moderately with increasing air gap (dose increased by 2-6%) and increased weakly with increasing SOBP width (dose change <4%). In all cases examined, the effects were largest at shallow depths. We concluded that the dose deposited by edge-scattered protons can distort the dose proximal to the target with varying contributions due to the proton range, treatment field size, collimator position and thickness, and width of the SOBP. Our findings also suggest that accurate predictions of dose per monitor-unit calculations may require taking into account the dose from protons scattered from the edge of the patient-specific collimator, particularly for fields of small lateral size and deep depths.

A Monte Carlo model for out-of-field dose calculation from high-energy photon therapy.

As cancer therapy becomes more efficacious and patients survive longer, the potential for late effects increases, including effects induced by radiation dose delivered away from the treatment site. This out-of-field radiation is of particular concern with high-energy radiotherapy, as neutrons are produced in the accelerator head. We recently developed an accurate Monte Carlo model of a Varian 2100 accelerator using MCNPX for calculating the dose away from the treatment field resulting from low-energy therapy. In this study, we expanded and validated our Monte Carlo model for high-energy (18 MV) photon therapy, including both photons and neutrons. Simulated out-of-field photon doses were compared with measurements made with thermoluminescent dosimeters in an acrylic phantom up to 55 cm from the central axis. Simulated neutron fluences and energy spectra were compared with measurements using moderated gold foil activation in moderators and data from the literature. The average local difference between the calculated and measured photon dose was 17%, including doses as low as 0.01% of the central axis dose. The out-of-field photon dose varied substantially with field size and distance from the edge of the field but varied little with depth in the phantom, except at depths shallower than 3 cm, where the dose sharply increased. On average, the difference between the simulated and measured neutron fluences was 19% and good agreement was observed with the neutron spectra. The neutron dose equivalent varied little with field size or distance from the central axis but decreased with depth in the phantom. Neutrons were the dominant component of the out-of-field dose equivalent for shallow depths and large distances from the edge of the treatment field. This Monte Carlo model is useful to both physicists and clinicians when evaluating out-of-field doses and associated potential risks.